



YOUNG ONCOLOGIST CLUB

# XIII INTERNATIONAL MEETING OF YOUNG ONCOLOGIST CLUB

## Deep Dive in Oncology - Precision, Prediction and Progress

Hyatt Regency Pravets, May 15-17, 2026

### PROGRAMME

#### FRIDAY, MAY 15, 2026 (DAY 1)

##### Hall Pravets 1

10.45 - 11.00 Conference opening/Welcome addresses - Young Oncologist Club Bulgaria,  
Balkan Investigation Network of Oncology, European Chinese Alliance of Oncology

##### LUNG CANCER SESSION

Moderators: Chr. Manegold & P. Balikova & G. Ganev

11.00 - 11.15 IO Strategy for Lung Cancer NSCLC in Specific Population, J. Arabadjiev, Keynote lecture

11.15 - 11.45 Peri-operative Therapies for Wild Type Resectable NSCLC: How to Choose IO in Daily Practice,  
L. Pilz

11.45 - 12.15 Challenges for Pathologists in Lung Cancer Diagnosis, M. Papotti, Keynote lecture

12.15 - 12.30 Metastatic EGFR-Mutant NSCLC - First Line Treatment: Combination or Monotherapy?, S. Alves

12.30 - 12.45 Long-Term Cancer Survival after COVID-19: Nationwide Evidence in Patients with  
Solid Malignancies, G. Dimitrov

12.45 - 13.00 New Treatment Strategies in Management of SCLC, S. Baka

13.00 - 13.15 Lung Cancer Treatment: Past, Present, Future, N. Chilingirova

13.15 - 13.30 From "Undruggable" to Actionable: KRAS Inhibition in NSCLC, Hui Wang

13.30 - 14.30 Lunch

14.30 - 15.00 Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours:  
Advances, Combination Strategies, and Future Directions, I. Virgolini, Keynote Lecture

15.00 - 16.00 Interactive Tumor Board - R. Krasteva, J. Arabadjiev, Chr. Manegold, N. Chilingirova,  
P. Castellucci, M. Papotti, B. Iliev, P. Balikova, G. Ganev, Ts. Tatarov, A. Konsoulova

## Hall Pravets 1

- 16.00 – 17.00 Bayer Symposium  
Personalization of Treatment in mHSPC: Optimizing Efficacy and Quality of Life  
Moderator: R. Krasteva
- ▶ Why the Personalization is Important in mHSPC?, S. Touncheva
  - ▶ Optimizing Clinical Outcomes in mHSPC, B. Iliev
  - ▶ Improving Efficacy and Quality of Life in Prostate Cancer Treatment, Ts. Tatarov
- 17.00 – 17.40 Johnson&Johnson Symposium  
Progress in the Treatment of NSCLC with EGFR Mutations - Now and in the Future  
Moderator: J. Arabadjiev
- ▶ Redefining First - and Second - line Therapy: Evolving Strategies with Combination Approaches for Common EGFR mutant NSCLC, S. Alves
  - ▶ Evidence in Action: From Evidence into Practice: Real-world Clinical Cases, S. Bakalov
- 17.40 – 18.20 Pfizer Symposium  
Balancing Efficacy and Safety in Precision Oncology  
Moderator: R. Krasteva
- ▶ Loratinib - Toxicity Management without Compromising the Clinical Benefit, B. Iliev
  - ▶ Palbociclib – a Deep Dive into SABCS 2025 Data, P. Balikova
- 18.20 – 19.00 Medison Symposium  
EMPOWERing First Line Treatment: Cemiplimab in Advanced NSCLC, M. Jakopovic, J. Arabadjiev, P. Tsenova
- 20.00 – 23.00 Dinner

## Hall Borovets

- 16.00 – 19.00 Pathology Workshop - Lung Cancer: How to Differentiate Second Primary Tumors from Metastatic Disease, M. Papotti

## Hall Pravets 2

- 16.00 – 16.40 Pierre Fabre Symposium  
BRAF Insights: Bridging Science, AI and Clinical Practice  
Moderator: J. Arabadjiev
- ▶ Treatment Strategies in BRAFV600E-mutant mCRC: The Right Treatment for the Right Patient, Tsv. Tatarov
  - ▶ Advancing Care in BRAFV600-mutant Metastatic Melanoma: Harnessing Real-world Evidence to Personalize Care, B. Murdzhev
- 16.40 – 17.00 Lonquex® - a Proven Solution with a History and a Look into the Future of G-CSF Therapies, S. Katov - Teva Lecture
- 17.00 – 17.20 Servier Lectures - Evolving Treatment in Metastatic Pancreatic Cancer
- ▶ ONIVYDE®: Specifically Designed to Fight Pancreatic Cancer Alongside your Patients, S. Nedeva
  - ▶ ONIVYDE®: Real World Data and Everyday Experience, M. Dacheva-Dimitrova
- 17.20 – 17.40 Between Diagnosis and the Patient: The Physician's Difficult Choices in mCRC Care, V. Donkina - Amgen Lecture
- 17.40 – 18.00 Fruzaqla: A New Opportunity in the Treatment of mCRC, B. Iliev - Takeda Lecture
- 18.20 – 19.20 Roche Symposium  
Care for LC and BC Patients: The Evolving Treatment Paradigm  
Moderator: R. Krasteva
- ▶ Atezolizumab as a Standard in the Treatment of Patients with Extensive-stage Small Cell Lung Cancer Proven in the Real Clinical Practice, R. Krasteva
  - ▶ Monotherapy with Atezolizumab in Patients with Advanced NSCLC who are Unsuitable for Platinum-Based Treatment and have any PD-L1 Expression, Vl. Milov
  - ▶ Treatment Strategies for Optimized Patient Outcomes in HER2+ Early Breast Cancer, Tsv. Yordanov

## SATURDAY, MAY 16, 2026 (DAY 2)

### Hall Pravets 1

#### BREAST CANCER SESSION

Moderators: A. Fakirova & Y. Yordanov & F. Pehlivan

- 09.00 – 09.30 Evolving Paradigms in Early Breast Cancer: Multidisciplinary Intercity Insights – Panel Discussion, F. Zagouri, G. Zografos, R. Krasteva, Y. Yordanov, A. Fakirova
- 09.30 – 09.45 Germline and Somatic Biomarkers in Breast Cancer: Relevance in Contemporary Pharmacotherapeutic Guidelines, S. Popovska, Z. Kamburova
- 09.45 – 10.00 Integrating Artificial Intelligence and Biomarker Analysis: Deciphering the Role of Androgen Receptor in Breast Cancer, S. Bachurska
- 10.00 – 10.15 Clinical Features and Risk Factors of Trastuzumab Induced Cardiovascular Toxicity in Breast Cancer, Zhongjing Ma
- 10.15 – 10.30 Breast Cancer News from 2025 - How Do We Think since the Last Monday? , A. Konsoulova
- 10.30 – 10.45 Hybrid SPECT/CT for Preoperative Sentinel Lymph Node Mapping in Breast Cancer Patients After Neoadjuvant Chemotherapy, M. Mihaylova
- 10.45 – 11.00 What is New on the Horizon in mTNBC, K. Punie

#### RADIOTHERAPY SESSION

- 11.00 – 11.15 Stereotactic Radiosurgery for Brain Metastases in the Era of Precise Systemic Therapy, D. Dimov
- 11.15 – 11.30 Stereotactic Radiosurgery for Liver Metastases: Effectiveness and Integration into Systemic Therapy Regimes, G. Ganev

#### OTHER CANCER LOCALIZATIONS SESSION

Moderators: G. Ganev & A. Kontilev & S. Touncheva

- 11.30 – 12.00 Hydrogen Sulfide as a Biomarker to Predict the Individual Risk of People to Develop Colorectal Cancer, W. Voigt
- 12.00 – 12.15 PET/CT Imaging in Stomach Cancer, S. Sergieva
- 12.15 – 12.35 PRRT in Prostate Cancer: Advances, Combinations, Strategies and Future Directions, P. Castellucci, Keynote lecture
- 12.35 – 12.50 Neoadjuvant Therapy in Resectable High-Risk Melanoma: From Clinical Evidence to Practical Application, I. Gavrilova
- 12.50 – 13.05 How to Work Safely with Hazardous Drugs, V. Grigorova, R. Krasteva
- 13.05 – 14.00 Lunch
- 14.00 – 14.15 Is Extended Lymph Node Dissection Becoming Unnecessary? Rethink the Role of Sentinel Lymph Node Biopsy in High-Risk Prostate Cancer, V. Hadzhyiska
- 14.15 – 14.30 Insufficiencies in Oncology Care - Advanced Systemic Treatment, Poor Outcomes. Why do we not Dare to Ask and Analyze?, Tsv. Yordanov
- 14.30 – 14.45 Imaging Modalities for Nasopharyngeal and Oropharyngeal Malignancies in Adults: Advantages and Disadvantages, S. Beyti, Pl. Getsov
- 14.45 – 15.30 Crossroad Young Oncologists – Panel Discussion – Interactive Session - B. Iliev, G. Dimitrov
- 15.30 – 15.45 Is HRD Status Enough as a Determinant of PARP Inhibitor Benefit in mCRPC?, G. Dimitrov
- 15.45 – 16.00 Construction of Comprehensive Oncology Center and Introduction of AI MDT Experience of SPH, Chunxia Su

## Hall Pravets 1

16.00 – 17.00 Swixx BioPharma Symposium  
Optimizing Therapy in Melanoma with Nivolumab + Relatlimab:  
Clinical Results, Practical Experience, and Patient Selection Criteria

Moderator: R. Krasteva

- ▶ Nivolumab + Relatlimab in Melanoma Treatment: New Horizons, Clinical Experience, and Precise Patient Selection, M. Mandalà – Keynote Lecture
- ▶ Clinical Case: Patient Selection in the Context of 4-Year Data from RELATIVITY-047", A. Kontilev
- ▶ First Steps with Nivolumab + Relatlimab in Bulgaria: Early Clinical Experience and Observations, B. Iliev

17.00 – 18.00 MSD Symposium  
Improving Holistic Care in Advanced Endometrial and Cervical Cancer - The New Era

Moderator: J. Arabadjiev

- ▶ The Potential of Immunotherapy in Treatment of First Line Endometrial Cancer, T. Zlatanova
- ▶ Optimizing Management of Locally Advanced Cervical Cancer, R. Krasteva

18.00 – 19.00 Astellas Symposium  
Lighting the Way for Targeted Treatment in Advanced G/GEJ Adenocarcinoma

Moderator: R. Krasteva

- ▶ Biomarkers Development in G/GEJ Cancer. Testing of CLDN18.2 in Clinical Practice, S. Batchurska
- ▶ Focus on SPOTLIGHT and GLOW, R. Krasteva
- ▶ Individualizing Targeted Therapy in G/GEJ Cancer, B. Murdzhev

19.00 – 20.00 Novartis Symposium

Moderator: R. Krasteva

- ▶ A Step Forward in the Adjuvant Treatment of HR+/HER2- Breast Cancer, F. Zagouri
  - ▶ Translating Science into Clinical Practice, B. Iliev, S. Usheva
- Discussion: R. Krasteva, F. Zagouri, B. Iliev, S. Usheva

## Hall Pravets 2

16.00 – 17.00 Eli Lilly Symposium

Moderator: G. Dimitrov

- ▶ Treating HR+,HER2- MBC in Endocrine Sensitive Patients, B. Iliev
- ▶ Treating HR+,HER2- MBC in Patients with Endocrine Resistance, S. Nedeva
- ▶ Importance of Identification of High-Risk in HR+, HER2- EBC with Nodal Involvement, D. Manov
- ▶ AE Management During the Treatment with Verzenio, Y. Dimitrova

17.00 – 17.20 Clinical Experience with Elahere – A New Standard in the Treatment of Platinum-Resistant Ovarian Cancer, A. Changalova - AbbVie Lecture

17.20 – 17.40 Personalized Treatment Goals in aUC: Subgroup Analyses from the JAVELIN Bladder 100 and a Clinical Case of aRCC, P. Balikova - Merck Lecture

17.40 – 18.40 Astra Zeneca Symposium  
State-of-the-Art Precision Oncology: Innovation in Breast, Endometrial, Gastric and Lung Cancer Treatment

Moderator: P. Balikova

- ▶ Expanding Options Beyond ET in the Treatment of HR+ mBC, K. Punie
- ▶ Response that Endures: IO + PARPi – 2 Times Longer Duration of Response in the Treatment of Advanced/Recurrent pMMR Endometrial Carcinoma, B. Iliev
- ▶ Long awaited and Meaningful Step toward Cure: Perioperative Treatment of Early Gastric or Gastroesophageal Junction Cancer with IMFINZI + FLOT, B. Iliev
- ▶ The POSEIDON Regimen: IMFINZI + IMJUDO + ChT - the Only Combination Immunotherapy Regimen with a Short Course of Anti-CTLA-4 Treatment, T. Zlatanova

### POSTER SESSION 09.00 – 19.00

20.00 – 20.15 Poster Awards

20.15 – 23.00 Dinner